Jean‐Marie Michot

16.0k total citations · 4 hit papers
199 papers, 5.7k citations indexed

About

Jean‐Marie Michot is a scholar working on Oncology, Pathology and Forensic Medicine and Molecular Biology. According to data from OpenAlex, Jean‐Marie Michot has authored 199 papers receiving a total of 5.7k indexed citations (citations by other indexed papers that have themselves been cited), including 124 papers in Oncology, 71 papers in Pathology and Forensic Medicine and 37 papers in Molecular Biology. Recurrent topics in Jean‐Marie Michot's work include Cancer Immunotherapy and Biomarkers (66 papers), Lymphoma Diagnosis and Treatment (63 papers) and CAR-T cell therapy research (34 papers). Jean‐Marie Michot is often cited by papers focused on Cancer Immunotherapy and Biomarkers (66 papers), Lymphoma Diagnosis and Treatment (63 papers) and CAR-T cell therapy research (34 papers). Jean‐Marie Michot collaborates with scholars based in France, United States and Italy. Jean‐Marie Michot's co-authors include Vincent Ribrag, Olivier Lambotte, Aurélien Marabelle, Stéphane Champiat, Pier Luigi Zinzani, Craig H. Moskowitz, Philippe Armand, Margaret A. Shipp, Jean‐Charles Soria and John Kuruvilla and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Jean‐Marie Michot

184 papers receiving 5.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Programmed Death-1 Blockade With Pembrolizumab in Patients With Classical Hodgkin Lymphoma After Brentuximab Vedotin Failure

2016 477 citations Philippe Armand, Margaret A. Shipp et al. profile →
Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study

2018 451 citations Jean‐Charles Soria, Jean‐Marie Michot et al. profile →
Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors

2018 376 citations Eléonora De Martin, Jean‐Marie Michot et al. profile →
Evaluation of Readministration of Immune Checkpoint Inhibitors After Immune-Related Adverse Events in Patients With Cancer

2019 272 citations Jean‐Marie Michot, Ariane Laparra et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Jean‐Marie Michot France	37	3.6k	1.3k	1.2k	1.1k	937	199	5.7k
Christos Emmanouilides United States	36	2.2k 0.6×	3.1k 2.4×	1.1k 0.9×	610 0.5×	1.4k 1.5×	96	5.8k
Loretta J. Nastoupil United States	34	3.2k 0.9×	2.4k 1.8×	685 0.6×	586 0.5×	285 0.3×	300	4.7k
Clara C. Chen United States	46	3.3k 0.9×	847 0.7×	1.4k 1.1×	1.2k 1.1×	1.6k 1.7×	99	8.9k
Patrick J. Stiff United States	46	4.1k 1.1×	2.3k 1.8×	1.3k 1.0×	1.4k 1.2×	1.4k 1.5×	247	8.4k
Alain Delmer France	41	2.2k 0.6×	3.0k 2.3×	823 0.7×	1.0k 0.9×	494 0.5×	197	5.2k
Ashley E. Winkler United States	10	3.9k 1.1×	815 0.6×	469 0.4×	1.1k 1.0×	2.5k 2.6×	12	7.3k
Cheolwon Suh South Korea	40	4.7k 1.3×	4.7k 3.6×	1.6k 1.3×	952 0.9×	1.5k 1.6×	413	7.8k
Yago Nieto United States	34	1.7k 0.5×	594 0.5×	609 0.5×	859 0.8×	440 0.5×	242	4.0k
Ulrich Mey Germany	25	1.5k 0.4×	1.0k 0.8×	387 0.3×	653 0.6×	416 0.4×	68	2.9k
Jan Walewski Poland	31	4.2k 1.2×	4.6k 3.5×	913 0.7×	710 0.6×	736 0.8×	214	7.0k

Countries citing papers authored by Jean‐Marie Michot

Since Specialization

Citations

This map shows the geographic impact of Jean‐Marie Michot's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jean‐Marie Michot with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jean‐Marie Michot more than expected).

Fields of papers citing papers by Jean‐Marie Michot

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jean‐Marie Michot. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jean‐Marie Michot. The network helps show where Jean‐Marie Michot may publish in the future.

Co-authorship network of co-authors of Jean‐Marie Michot

This figure shows the co-authorship network connecting the top 25 collaborators of Jean‐Marie Michot. A scholar is included among the top collaborators of Jean‐Marie Michot based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jean‐Marie Michot. Jean‐Marie Michot is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Laparra, Ariane, Stéphane Champiat, François‐Xavier Danlos, et al.. (2025). Immune-related adverse events occurring rapidly after a single dose of immune checkpoint blockade. Journal for ImmunoTherapy of Cancer. 13(9). e012756–e012756.

Michot, Jean‐Marie, Franck Morschhauser, Silvia Martina Ferrari, et al.. (2024). Longer Follow-up of Golcadomide (GOLCA), a Cereblon E3 Ligase Modulator (CELMoD™) Agent ± Rituximab (RTX), in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL). Blood. 144(Supplement 1). 869–869. 1 indexed citations

Lazarovici, Julien, et al.. (2023). Incidence, characteristics, management and outcome of patients with follicular lymphoma with tumor epidural compression, a study on 22 cases. Cancer/Radiothérapie. 27(5). 370–375. 1 indexed citations

Gazzah, Anas, Ratislav Bahleda, Antoine Hollebecque, et al.. (2023). Profile and outcome of cancer patients enrolled in contemporary phase I trials. European Journal of Cancer. 188. 1–7. 2 indexed citations

Michot, Jean‐Marie, Julio C. Chávez, Cecilia Carpio, et al.. (2023). OPEN‐LABEL PHASE 1/2 STUDY OF CC‐99282, A CEREBLON E3 LIGASE MODULATOR (CELMOD) AGENT ± RITUXIMAB, IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) NON‐HODGKIN LYMPHOMA (NHL). Hematological Oncology. 41(S2). 134–136.

Laparra, Ariane, François‐Xavier Danlos, Antoine Hollebecque, et al.. (2023). Immunosuppressant mycophenolate mofetil for patients with steroid-refractory immune-related hepatitis induced by checkpoint inhibitors in oncology. European Journal of Cancer. 193. 113313–113313. 11 indexed citations

Camus, Vincent, Aurélien Belot, Lucie Obéric, et al.. (2022). Outcomes of older patients with diffuse large B-cell lymphoma treated with R-CHOP: 10-year follow-up of the LNH03-6B trial. Blood Advances. 6(24). 6169–6179. 8 indexed citations

Ferlicot, Sophie, L. Rocher, Florent L. Besson, et al.. (2022). Renal involvement of lymphomas proven by kidney biopsy: report of 10 cases from a tertiary care center and comparison with the literature. International Journal of Hematology. 116(5). 678–695. 1 indexed citations

Kfoury, Maria, Anne-Laure Voisin, Stéphane Champiat, et al.. (2022). Analysis of the association between prospectively collected immune-related adverse events and survival in patients with solid tumor treated with immune-checkpoint blockers, taking into account immortal-time bias. Cancer Treatment Reviews. 110. 102452–102452. 35 indexed citations

10.

Aldea, Mihaela, Jean‐Marie Michot, François‐Xavier Danlos, Antoni Ribas, & Jean‐Charles Soria. (2021). Repurposing of Anticancer Drugs Expands Possibilities for Antiviral and Anti-Inflammatory Discovery in COVID-19. Cancer Discovery. 11(6). 1336–1344. 21 indexed citations

11.

Patel, Krish, Jean‐Marie Michot, Asher Chanan‐Khan, et al.. (2021). Safety and Anti-Tumor Activity of Plamotamab (XmAb13676), an Anti-CD20 x Anti-CD3 Bispecific Antibody, in Subjects with Relapsed/Refractory Non-Hodgkin's Lymphoma. Blood. 138(Supplement 1). 2494–2494. 19 indexed citations

12.

Sarkozy, Clémentine, Franck Morschhauser, Sydney Dubois, et al.. (2020). A LYSA Phase Ib Study of Tazemetostat (EPZ-6438) plus R-CHOP in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL) with Poor Prognosis Features. Clinical Cancer Research. 26(13). 3145–3153. 54 indexed citations

13.

Baldini, Capucine, P. Martin Romano, Anne-Laure Voisin, et al.. (2020). Impact of aging on immune-related adverse events generated by anti–programmed death (ligand)PD-(L)1 therapies. European Journal of Cancer. 129. 71–79. 63 indexed citations

14.

Aldea, Mihaela, Laura Mansi, Aurélien Marabelle, et al.. (2020). How to manage patients with corticosteroids in oncology in the era of immunotherapy?. European Journal of Cancer. 141. 239–251. 64 indexed citations

15.

Yap, Timothy A., Jane N. Winter, Lisa Giulino‐Roth, et al.. (2019). Phase I Study of the Novel Enhancer of Zeste Homolog 2 (EZH2) Inhibitor GSK2816126 in Patients with Advanced Hematologic and Solid Tumors. Clinical Cancer Research. 25(24). 7331–7339. 128 indexed citations

16.

Gauci, Marie-Léa, Émilie Lanoy, Stéphane Champiat, et al.. (2018). Long-Term Survival in Patients Responding to Anti–PD-1/PD-L1 Therapy and Disease Outcome upon Treatment Discontinuation. Clinical Cancer Research. 25(3). 946–956. 106 indexed citations

17.

Michot, Jean‐Marie, Réda Bouabdallah, Jeanette K. Doorduijn, et al.. (2017). CC-122, a Novel Cereblon Modulating Agent, in Combination with Obinutuzumab (GA101) in Patients with Relapsed and Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (NHL). Blood. 130. 411–411. 3 indexed citations

18.

Aftimos, Philippe, Christian Rolfo, Sylvie Rottey, et al.. (2017). Phase I Dose-Escalation Study of the Anti-CD70 Antibody ARGX-110 in Advanced Malignancies. Clinical Cancer Research. 23(21). 6411–6420. 47 indexed citations

19.

Thijssen, Rachel, Jennifer R. Brown, Stacey M. Fernandes, et al.. (2016). Dual TORK/DNA-PK inhibition blocks critical signaling pathways in chronic lymphocytic leukemia. Blood. 128(4). 574–583. 59 indexed citations

20.

Michot, Jean‐Marie, Philippe Armand, Vincent Ribrag, et al.. (2016). Pembrolizumab in patients with relapsed/refractory primary mediastinal large B-cell lymphoma (rrPMBCL) or relapsed or refractory Richter syndrome (rrRS): Phase 2 KEYNOTE-170 study. Annals of Oncology. 27. vi325–vi325. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact